^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) + buparlisib (AN2025) (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Published date:
09/04/2020
Excerpt:
In this open-label, multicenter, phase Ib study, 70 postmenopausal women with HR+, HER2- ABC were enrolled...ribociclib plus buparlisib plus fulvestrant...The highest overall response rate was seen in the buparlisib triple combination (25.0%, 95% confidence interval, 9.8-46.7%).
Secondary therapy:
fulvestrant
DOI:
10.1158/1078-0432.CCR-20-0645
Trial ID:
